A clinical scoring system to identify patients with sebaceous neoplasms at risk for the Muir-Torre variant of Lynch syndrome

Genet Med. 2014 Sep;16(9):711-6. doi: 10.1038/gim.2014.19. Epub 2014 Mar 6.

Abstract

Purpose: The Muir-Torre syndrome variant of Lynch syndrome is characterized by the presence of sebaceous neoplasms (adenoma, epithelioma/sebaceoma, carcinoma) and Lynch syndrome-associated cancers (colon, endometrial, and others). Several clinical scoring systems have been developed to identify patients with colon cancer at high risk of Lynch syndrome. However, no such system has been described for patients presenting with sebaceous neoplasms.

Methods: Based on logistic regression analysis, a scoring system was developed for patients with sebaceous neoplasm to identify those with the highest likelihood of having Muir-Torre syndrome. The final version of the scoring system included variables such as age at presentation of initial sebaceous neoplasm, total number of sebaceous neoplasms, personal history of a Lynch-related cancer, and family history of Lynch-related cancers.

Results: Patients with a score of 3 or more were more likely to have Muir-Torre syndrome (28 of 29 patients), those with a score of 2 had intermediate likelihood (12 of 20 patients), and no patient with a score of 0 or 1 was diagnosed with Muir-Torre syndrome.

Conclusion: The Mayo Muir-Torre syndrome risk scoring system appears to identify whether patients who present with sebaceous neoplasms are in need of further Lynch syndrome evaluation using easily ascertained clinical information. Abnormal mismatch repair gene immunohistochemistry of a sebaceous neoplasm is a poor predictor in regard to diagnosing Lynch syndrome.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Age of Onset
  • Aged
  • Aged, 80 and over
  • Comorbidity
  • Female
  • Genetic Association Studies
  • Genetic Loci
  • Germ-Line Mutation
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Muir-Torre Syndrome / epidemiology*
  • Muir-Torre Syndrome / etiology*
  • MutS Homolog 2 Protein / genetics
  • Mutation
  • Risk Factors
  • Risk*
  • Sebaceous Gland Neoplasms / complications*
  • Sebaceous Gland Neoplasms / diagnosis

Substances

  • MSH2 protein, human
  • MutS Homolog 2 Protein